Showing 4801-4810 of 5623 results for "".
- Laboratory Studies Confirm Betadine Antiseptic Products’ Effectiveness Against COVID-19 Virushttps://modernod.com/news/laboratory-studies-confirm-betadine-antiseptic-products-effectiveness-against-covid-19-virus/2477989/Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2). Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2477985/Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in
- Apellis Completes Enrollment in Two Phase 3 Studies of Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-completes-enrollment-in-two-phase-3-studies-of-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2477978/Apellis Pharmaceuticals announced that it completed enrollment in the phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan (APL-2), a targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA causes blind
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- Patrick F. Williams Appointed Chief Financial Officer of Staar Surgicalhttps://modernod.com/news/patrick-f-williams-appointed-chief-financial-officer-of-staar-surgical/2477969/Staar Surgical announced that Patrick F. Williams has joined the company as Chief Financial Officer, effective today. Mr. Williams is reporting to Caren Mason, President and Chief Executive Officer. His appointment is part of a planned transition following Deborah Andrews’ previously announced re
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- Global COVID-19 Prevention Trial of Hydroxychloroquine to Resumehttps://modernod.com/news/global-covid-19-prevention-trial-of-hydroxychloroquine-to-resume/2477960/A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators, according to a Reuters report. The Medic
- Oculight Launches US Subsidiary OCU L&Chttps://modernod.com/news/oculight-launches-us-subsidiary-ocu-lc/2477956/Oculight announced the launch of OCU L&C, a fully-owned U.S. subsidiary. OCU L&C will focus on the commercialization of its products in the U.S. Oculight is an ophthalmic medical device developer based in Korea founded in 2017 by Dr.
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s